<DOC>
	<DOCNO>NCT01659554</DOCNO>
	<brief_summary>The primary objective study investigate feasibility , tolerability safety surgical debulking resection heat intraoperative chemotherapy ( HIPEC ) follow repeat intraperitoneal chemotherapy treatment recurrent ovarian , primary peritoneal , fallopian tube carcinoma .</brief_summary>
	<brief_title>A Phase II Combined Modality Protocol Debulking Surgery With HIPEC Followed Intraperitoneal Chemotherapy Treatment Recurrent Ovarian , Primary Peritoneal &amp; Fallopian Tube Cancers</brief_title>
	<detailed_description>This phase II , open label , single center study surgery follow heat intraoperative cisplatin patient recurrent ovarian , primary peritoneal fallopian tube cancer . Approximately twenty patient receive surgery intraoperative ( hyperthermic ) cisplatin follow four consecutive course outpatient intraperitoneal cisplatin doxorubicin give day 1 8 3 week cycle .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Patients must histologically confirm ovarian , primary peritoneal fallopian tube carcinoma . 2 . Patients must measurable evidence recurrent intraabdominal disease base Computed tomography ( CT scan ) finding . 3 . Patients must fulfill follow regard prior chemotherapy : 1 . 4 week great since conclusion prior chemotherapy ; 2 . Prior intraperitoneal chemotherapy cisplatin acceptable ; , 3 . Prior systemic chemotherapy acceptable . 4 . Patients must Karnofsky Performance Status &gt; 70 % 5 . Patients must estimate life expectancy least 16 week . 6 . Patient assurance study compliance geographic proximity allow adequate followup . 7 . Patients must adequate organ function screen visit define follow laboratory value : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin ≥8 g/dL Albumin ≥ 2 g/dL Total Bilirubin ≤ 2.5 x ULN* Alkaline phosphatase ≤ 3.0 x ULN* Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 x ULN Creatinine ≤ 1.5 x ULN 8 . Patient must sign informed consent 9 . Patient must least 18 year age 10 . Following cytoreductive surgery , patient 's residual disease large 1cm Receive HIPEC continue normothermic IP chemotherapy Exclusion criterion : 1 . Have active peripheral neuropathy Grade 2 great intensity , define National Cancer Institute ( NCI ) Common Toxicity Criteria Adverse Events ( CTCAE ; Version 4 ) . 2 . Have experience myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure ( see section 16.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . 3 . Prior radiation therapy within 4 week enrollment . 4 . Have uncontrolled active systemic infection require therapy . 5 . Have history allergic reaction attributable compound contain boron mannitol hypersensitivity reaction drug formulate polysorbate 80 . 6 . Have serious concomitant systemic disorder ( include oncologic emergency ) incompatible study ( discretion investigator ) . 7 . Have `` currently active '' second malignancy nonmelanoma skin cancer carcinoma situ cervix register . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . 8 . Have investigational agent within 4 week enrollment study . 9 . Have history serious medical psychiatric illness prevent informed consent , opinion investigator , would make patient poor study candidate . 10 . Evidence extraabdominal metastasis preinclusion thoracic compute tomography ( CT ) scan ( i.e . brain chest disease ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Primary peritoneal</keyword>
</DOC>